skip to Main Content
RallyBio Conference Room

Rallybio reports positive data in its clinical program for the prevention of fetal and neonatal alloimuune thrombocytopenia (FNAIT)

Rallybio today announced data from its ongoing Phase 1/2 study of RLYB211 showing significant benefit over placebo.

Back To Top